396 related articles for article (PubMed ID: 19144985)
1. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Boehme V; Schmitz N; Zeynalova S; Loeffler M; Pfreundschuh M
Blood; 2009 Apr; 113(17):3896-902. PubMed ID: 19144985
[TBL] [Abstract][Full Text] [Related]
2. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Schmitz N; Zeynalova S; Glass B; Kaiser U; Cavallin-Stahl E; Wolf M; Haenel M; Loeffler M; Truemper L; Pfreundschuh M
Ann Oncol; 2012 May; 23(5):1267-1273. PubMed ID: 21989328
[TBL] [Abstract][Full Text] [Related]
3. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Boehme V; Zeynalova S; Kloess M; Loeffler M; Kaiser U; Pfreundschuh M; Schmitz N
Ann Oncol; 2007 Jan; 18(1):149-157. PubMed ID: 17018708
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
[TBL] [Abstract][Full Text] [Related]
7. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
8. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
9. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
10. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
[TBL] [Abstract][Full Text] [Related]
11. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
12. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
David RJ; Baran A; Loh KP; Casulo C; Barr PM; Friedberg JW; Reagan PM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):781-787. PubMed ID: 30262330
[TBL] [Abstract][Full Text] [Related]
13. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
15. Response: Intrathecal methotrexate and central nervous system events.
Schmitz N; Zeynalova S; Loeffler M; Pfreundschuh M;
Blood; 2009 Aug; 114(9):1999-2000. PubMed ID: 19713481
[No Abstract] [Full Text] [Related]
16. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
[TBL] [Abstract][Full Text] [Related]
17. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
18. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Barta SK; Lee JY; Kaplan LD; Noy A; Sparano JA
Cancer; 2012 Aug; 118(16):3977-83. PubMed ID: 22180164
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
Czuczman MS; Grillo-López AJ; White CA; Saleh M; Gordon L; LoBuglio AF; Jonas C; Klippenstein D; Dallaire B; Varns C
J Clin Oncol; 1999 Jan; 17(1):268-76. PubMed ID: 10458242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]